Movement Alert｜Argenx SE Overnight fall 5.22%, shares pressured ahead of quarterly results

Market Focus10-22

On October 22, Argenx SE fell 5.22% Overnight, trading at $843.6/share, with turnover of $1.374 million.

The move was closely tied to earnings expectations, with the company scheduled to report its new quarterly results before the market and consensus projecting EPS of $7.44.

Background developments help explain the heightened sensitivity: Argenx SE previously reported positive phase 3 data for Vyvgart Hytrulo in autoimmune myositis in August, which supported valuation, but discontinued a phase 3 Sjogren's disease trial in October after a futility review, pressuring sentiment. At the same time, phase 2 FB102 data in celiac disease met its primary endpoint and has been viewed by analysts as an important support for sentiment recovery.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment